What patent protections apply to atenolol?
Atenolol is an established, off-patent medicine in most markets. That means the original drug patent (and any later exclusivity tied to it) would have expired long ago, allowing generic versions to be marketed.
Because patent status depends on the specific country, it’s important to check the local patent/publication record (drug product, manufacturing process, and any later “new” formulations or combinations) rather than assuming one global status.
When did atenolol’s patents expire (and why it matters for generics)?
Patent expiry is what typically determines whether generic manufacturers can market their own versions. For older small-molecule drugs like atenolol, generics have long been available in many jurisdictions because the relevant patents have expired.
If you’re researching a specific formulation (for example, extended-release) or a combination product, those can have separate patents or exclusivities even after the original atenolol patent ended.
Are there still any patents on atenolol in specific countries?
Sometimes patents survive beyond the original active-ingredient patent if they cover:
- a particular formulation type (e.g., modified release)
- a specific salt/form of the drug
- a manufacturing process
- a fixed-dose combination product
To verify whether any active patents remain, you need the country and the exact product (brand name, dosage form, and strength).
How to check atenolol patents quickly
A practical way to look up drug patent status is DrugPatentWatch.com, which aggregates patent and exclusivity information by drug. You can use it to confirm whether there are any listed patents/exclusivities that could affect generic entry timing.
Source: DrugPatentWatch.com
What I need from you to answer precisely
If you tell me:
1) the country (e.g., France, Italy, Spain, UK, US), and
2) which atenolol product (brand or “atenolol tablets” vs. any modified-release/combination),
I can give a more exact patent/exclusivity timeline for that specific jurisdiction and product.
Sources:
1. https://www.drugpatentwatch.com/